Data from a phase III trial involving patients with 1p/19q non-co-deleted anaplastic glioma indicate that adjuvant temozolomide, administered either concurrent with, or immediately following radiotherapy, provides a significant improvement in overall survival duration, compared with radiotherapy alone (HR 0.65; P = 0·0014). Grade 3–4 adverse events, which were mostly haematological, were observed in 8–12% of patients. Whether or not temolozomide administered concurrently with radiotherapy is superior to temozolamide following radiotherapy has yet to be revealed.
References
van den Bent, M. J. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31442-3 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Temozolomide improves outcomes. Nat Rev Clin Oncol 14, 648 (2017). https://doi.org/10.1038/nrclinonc.2017.145
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.145
